- In April 2023, Nova Eye Medical Ltd. obtained FDA 510(k) clearance for its canaloplasty device, iTrack Advance, designed to lower intraocular pressure (IOP) in adult patients with primary open-angle glaucoma
- In August 2022, Glaukos Corp. received FDA 510(k) clearance for iStent Infinite, a standalone device for reducing elevated IOP in primary open-angle glaucoma patients
- In July 2022, iSTAR Medical entered a strategic partnership with AbbVie to expand AbbVie's portfolio of glaucoma treatments, offering patients additional care options
- In June 2022, AbbVie announced a USD 60 million deal for the rights to acquire iSTAR Medical, a Belgian firm developing the minimally invasive MINIject glaucoma device, now in a U.S. premarket approval study. AbbVie is collaborating on the development and commercialization of the device
- In June 2022, Iridex Corporation secured regulatory approval from China’s National Medical Products Administration (NMPA) to market and sell its Cyclo G6 platform for glaucoma treatment
